Hamish Ryder joins Drug Target Review Advisory Board
Prior to joining CRT-DL, Dr Ryder held positions in pharmaceutical and biotech companies for over 20 years …
Hamish Ryder, Director of Drug Discovery at Cancer Research UK Therapeutic Discovery Laboratories, has joined the editorial advisory board of Drug Target Review.
Dr Ryder has directed drug discovery at CRUK-TDL, and its predecessor CRT-DL, since 2008. He has led the successful transition of its translational strategy to a themed multi-project alliance model where industry partners are involved from the earliest stages of target selection and triage.
Prior to joining CRT-DL, Dr Ryder held positions in pharmaceutical and biotech companies for over 20 years, the most recent of which was as Director of Research at Almirall, Spain’s largest pharmaceutical company. He has worked in a number of therapeutic areas, including autoimmune, inflammatory, respiratory, GI, CNS and cancer.
Dr Ryder has led organisations that have discovered multiple candidate drugs for regulatory development, thus far resulting in approved therapies for chronic obstructive pulmonary disease (Bretaris and Duaklir). He obtained his first degree in Natural Sciences and a PhD in organic chemistry from the University of Cambridge.
Chronic obstructive pulmonary disease (COPD)
Cancer Research UK, Cancer Research UK Therapeutic Discovery Laboratories